Why Pharming Group (ENXTAM:PHARM) Is Up 22.9% After Raising Guidance and Leniolisib’s FDA Progress

• On November 6, 2025, Pharming Group N.V. reported strong quarterly earnings with nine-month sales of US$269.6 million, up from US$204.53 million the previous year, and raised its full-year 2025 revenue guidance to between US$365 million and US$375 million.
• A key development was the company's announcement that the FDA granted priority review for leniolisib's potential pediatric label expansion, signaling further growth opportunities for its rare disease portfolio.
• With robust revenue momentum and updated guidance, we'll look at how Pharming's progress on leniolisib shapes its investment narrative.

This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.

What Is Pharming Group's Investment Narrative?

To see Pharming Group as an appealing long-term investment, you have to believe in the company’s ability to grow its rare disease portfolio and maintain momentum behind leniolisib, both for current and new patient groups. The latest quarterly results point to substantial revenue growth and improved bottom-line performance, driven by an expanding product suite and stronger commercial execution. The FDA’s priority review for leniolisib’s pediatric label expansion now sits at the center of the short-term story, presenting a potentially material catalyst heading into early 2026. Meanwhile, management’s upgraded full-year revenue outlook for 2025, paired with evidence of accelerating sales, helps to reduce near-term uncertainty and support the bullish narrative. That said, major risks remain, including regulatory outcomes, the dependency on a limited number of therapies, and ongoing earnings volatility. Overall, fresh momentum from recent achievements could amplify both opportunity and risk.

But against this optimism, regulatory outcomes for leniolisib remain a key risk worth monitoring. Pharming Group's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Seven individual fair value estimates from the Simply Wall St Community range from US$1.44 up to nearly US$7.91 per share, with multiple forecasts clustered at the lower end. Against this backdrop, attention turns to the pending FDA decision on leniolisib, which could influence both sentiment and Pharming’s business trajectory. Explore a variety of viewpoints to see how diverse investors size up the potential and risks.

Explore 7 other fair value estimates on Pharming Group - why the stock might be worth just €1.44!

Build Your Own Pharming Group Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Pharming Group research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Pharming Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pharming Group's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our top stock finds are flying under the radar-for now. Get in early:

• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 35 companies in the world exploring or producing it. Find the list for free.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com